相关实验视频

Updated: Jun 10, 2025

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

11.1K

低水平和新诊断的扩散性大B细胞淋巴瘤的预后

Jennifer J Gile1, Matthew Maurer2, Gordon J Ruan1

  • 1Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, United States.

The oncologist
|October 17, 2024
PubMed

Insights

低血清度与扩散性大B细胞淋巴瘤 (DLBCL) 患者的较差结果有关. 维持水平在2.0 mg/dL以上可能会改善这些人的生存率.

科学领域:

  • 在瘤学瘤学.
  • 血液学 血液学 血液学
  • 生物化学 生物化学

背景情况:

  • (Mg) 对于细胞功能至关重要.
  • 之前的研究表明,低血清Mg (<2.0 mg/dL) 与DLBCL患者自身干细胞移植 (SCT) 后更差的结果相关.

研究的目的:

  • 为了研究低血清的预后意义在以前未经治疗的扩散大B细胞淋巴瘤 (DLBCL) 患者.

主要方法:

  • 对408名未经治疗的DLBCL患者的血清度进行了分析.
  • 评估了两个切线点:低 (<1.7 mg/dL) 和低正常 (<2.0 mg/dL).

主要成果:

  • 23%的患者呈现出低正常血清水平 (<2.0 mg/dL).
  • 较低的正常与晚期疾病阶段,增加的外参与和更高的国际预后指数得分有关.
  • 低正常血清与明显较低的整体存活率 (OS) 和无事件存活率相关.

结论:

  • 低血清正常是未经治疗的DLBCL的潜在预后标志物.
  • 需要进一步的研究来探索Mg替代疗法的向水平>2.0 mg/dL,以潜在地提高患者的存活率.
抽象的

No abstract available in PubMed .

关键词:
的含量是多少? 的含量是多少?非霍奇金淋巴瘤的非霍奇金淋巴瘤.营养 营养 营养 营养生存分析,生存分析.

更多相关视频

Enhancing Tumor Content through Tumor Macrodissection10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

9.8K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

13.7K

相关概念视频

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
323
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K